Investors Press Releases Year All202320222021 Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial Sep 26, 2023 Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26 Sep 25, 2023 Omega Therapeutics to Participate in Two Upcoming Investor Conferences Sep 21, 2023 Omega Therapeutics Announces Updates to its Board of Directors Aug 29, 2023 Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress Aug 03, 2023 Omega Therapeutics Appoints Chris Schade to its Board of Directors Jul 12, 2023 Omega Therapeutics to Participate in Two Upcoming Investor Conferences Jun 01, 2023 Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting May 31, 2023 Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress May 04, 2023 Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting Apr 27, 2023
Year All202320222021 Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial Sep 26, 2023 Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26 Sep 25, 2023 Omega Therapeutics to Participate in Two Upcoming Investor Conferences Sep 21, 2023 Omega Therapeutics Announces Updates to its Board of Directors Aug 29, 2023 Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress Aug 03, 2023 Omega Therapeutics Appoints Chris Schade to its Board of Directors Jul 12, 2023 Omega Therapeutics to Participate in Two Upcoming Investor Conferences Jun 01, 2023 Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting May 31, 2023 Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress May 04, 2023 Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting Apr 27, 2023
